Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Botulinum Toxin Therapy of Social Anxiety Disorder

Botulinum Toxin Therapy of Social Anxiety Disorder Letters to the Editors Journal of Clinical Psychopharmacology Volume 39, Number 4, July/August 2019 2. Stallman HM, Kohler M, Wilson A, et al. BT into the glabellar region between May DISCUSSION Self-reported sleepwalking in Australian senior 2017 and October 2018. None of the pa- Guanfacine may suppress rapid eye move- secondary school students. Sleep Med. tients had hyperhidrosis. In 5 patients, ment sleep, modulate sleep architecture, 2016;25:1–3. previous and current pharmacologic and and can result in less sleepwalking. As a se- 3. De Cock VC. Sleepwalking. Curr Treat Options psychotherapeutic treatments had either lective α-adrenergic 2A agonist, it has the Neurol. 2016;18:1–9. been insufficient or were discontinued ability to regulate glutamatergic and catechol- secondary to side effects. All patients 4. Stallman HM, Kohler M. A systematic amine systems, both implicated in the neuro- review of treatments for sleepwalking: were maintained on their existing treat- chemistry of sleepwalking. Benzodiazepines 100 years of case studies. Sleep Hypnosis. ment regimen, and written consent was lessen sleepwalking through a sedative- 2016;1–22. obtained. SAnD symptoms were assessed hypnotic effect. Antidepressant medications 5. Fredriksson I, Jayaram-Lindström N, Wirf M, by the Leibowitz Social Anxiety Scale are thought to decrease sleepwalking owing et al. Evaluation of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Psychopharmacology Wolters Kluwer Health

Botulinum Toxin Therapy of Social Anxiety Disorder

Loading next page...
1
 
/lp/wolters-kluwer-health/botulinum-toxin-therapy-of-social-anxiety-disorder-a9eXGUtzhp

References (16)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0271-0749
eISSN
1533-712X
DOI
10.1097/JCP.0000000000001066
Publisher site
See Article on Publisher Site

Abstract

Letters to the Editors Journal of Clinical Psychopharmacology Volume 39, Number 4, July/August 2019 2. Stallman HM, Kohler M, Wilson A, et al. BT into the glabellar region between May DISCUSSION Self-reported sleepwalking in Australian senior 2017 and October 2018. None of the pa- Guanfacine may suppress rapid eye move- secondary school students. Sleep Med. tients had hyperhidrosis. In 5 patients, ment sleep, modulate sleep architecture, 2016;25:1–3. previous and current pharmacologic and and can result in less sleepwalking. As a se- 3. De Cock VC. Sleepwalking. Curr Treat Options psychotherapeutic treatments had either lective α-adrenergic 2A agonist, it has the Neurol. 2016;18:1–9. been insufficient or were discontinued ability to regulate glutamatergic and catechol- secondary to side effects. All patients 4. Stallman HM, Kohler M. A systematic amine systems, both implicated in the neuro- review of treatments for sleepwalking: were maintained on their existing treat- chemistry of sleepwalking. Benzodiazepines 100 years of case studies. Sleep Hypnosis. ment regimen, and written consent was lessen sleepwalking through a sedative- 2016;1–22. obtained. SAnD symptoms were assessed hypnotic effect. Antidepressant medications 5. Fredriksson I, Jayaram-Lindström N, Wirf M, by the Leibowitz Social Anxiety Scale are thought to decrease sleepwalking owing et al. Evaluation of

Journal

Journal of Clinical PsychopharmacologyWolters Kluwer Health

Published: Jan 1, 2019

There are no references for this article.